Christine Sagen Helgø
Mayor of Stavanger
Christine Sagen Helgø has been the mayor of Stavanger since the regional election of October 17th, 2011. Sagen Helgø represents the Conservative Party of Norway, Høyre. She has seen almost 18 years of Stavanger’s politics. Christine Sagen Helgø has been a member of the City Council in Stavanger from 1999, group leader for the Conservative Party from 2003-2011 and head of the municipal committee for urban development in Stavanger from 2007-2011. Sagen Helgø is also the president of the World Energy Cities group for the 2014-2016 term.
Bent Høie
The Minister of Health and Care
The Minister of Health and Care is responsible for hospitals, health services in the municipalities, general health care and mental health.
Henrik Lund

Henrik Lund

CEO Regenics AS, VP Clinical Development MC AstraZeneca 2005-2010, Chairmann Oslo Cancer Cluster, NCE, 2008-2018, and Co-Chair of 37 °C in 2018

Henrik Lund has a PhD in lipidology, post-doctoral training at UCSF, San Francisco, US. Henrik Lund served 10 years as Medical Director in AstraZeneca with leadership roles in drug development. 2005-2010 Vice President in AstraZeneca Clinical Development, overseeing global clinical trials. From 2010 CEO, Board positions in Norwegian biotechs, 2008-2018 in the Board/Chairman, Oslo Cancer Cluster, NCE. From 2014, CEO of Regenics AS, involved in tissue regeneration/wound treatment. 2017 EU Commision H2020 RIA expert.

Jon H. Kaspersen
Research Director, SINTEF and Co-Chair of 37 °C in 2018
Jon H Kaspersen has a PhD in turbulent flow characteristics. Kaspersen has since 1997 been employed by SINTEF. The first 10 years he was involved in research and development of guidance systems for minimal invasive surgery, health care information systems and telemedicine. Blood flow simulation (CFD) as well as fluid-structure interaction simulation was also important research topics.
From 2007 and up to recently, Kaspersen has been leading SINTEF Multiphase Flow Laboratory – the world largest laboratory of its kind. In March this year Kaspersen took on as Research Director for the Health Department at SINTEF Technology and Society.
Erik Halvorsen
In his role as Director of the TMC Innovation Institute, Erik keeps visionary new ideas moving through the TMCx accelerator, TMCx+ incubator and TMC Biodesign Fellowship Program, while playing an instrumental role in JLABS @TMC, the AT&T Foundry for Connected Health@TMC, the TMC advisor/mentor network and the emerging innovation funding infrastructure.
Before joining the Texas Medical Center in 2015, Erik made his mark in New England, serving as senior executive director of Technology Transfer & Industry Collaborations at Tufts University, following seven years as executive director of the Technology & Innovation Development Office (TIDO) for Boston Children’s Hospital. In both positions, Erik was responsible for accelerating and translating research and innovations into new health care products. He was also managing partner of Children’s First Technology Development Fund for pediatric-focused advancements.
Prior to that, Erik supported early-stage therapeutic, device, diagnostic, digital health and robotics companies across the Harvard University system for 12.5 years. His Harvard leadership roles included director of Business Development, Harvard Stem Cell Institute (HSCI); director of Business Development, Harvard Office of Technology Development; and licensing associate/officer, Harvard University OTTL. His earlier experience includes project manager at Spinner Technologies and licensing associate at the University of Virginia Patent Foundation.
Erik holds a Bachelor of Arts from the University of Virginia (1994), a Master of Science in human anatomy from the Medical College of Virginia (1995) and Doctor of Philosophy in Neuropharmacology from University of Virginia (2000).
When championing new ideas, Erik assumes whatever role is necessary to improve the likelihood of success—coach, cheerleader, general manager or ball boy. As a result, he has been invited to join numerous boards and associations, including the JIBO Advisory Board, Claritas Genomics Board of Directors, OPENPediatrics Advisory Board, Tetraphase Pharmaceuticals Board of Directors, the Association of University Technology Managers, Massachusetts Association of Technology Transfer Officers, Massachusetts Biotechnology Council and Boston Top 40 Under 40.
He has also partnered with countless health care and business enterprises, from IBM, Google and GE to Medtronic, Pfizer and GSK, as well as with a wide range of venture capital firms. With experience running clinical trials, Erik has a passion for removing development obstacles so new solutions can quickly reach people in need.

Stephen McAdam
Global Technical Director DNV GL Healthcare

Stephen McAdam is currently Global Technical Director at DNV GL Healthcare. With 300 offices in over 100 countries, DNV GL is uniquely positioned to serve the needs of the global healthcare community, having certified or accredited over 2,000 healthcare organizations.
An immunologist by training, Stephen spent much of his early career in laboratories working with pathogens such as HIV and HCV in hospitals in the United States, Africa, and Europe. In 2001 Stephen moved to DNV GL’s Research department to head up the Healthcare and Biorisk program where he was responsible for exploring how systems-based approaches to management and risk assessment can be adapted and applied to areas related to patient safety and to biorisk. Stephen has collaborated many of the world’s leading organizations in the area of biorisk management, including the WHO, European Centre for Disease Prevention and Control, the Canadian Science Centre, the UK health Protection Agency, and GSK.
In his current role Stephen is responsible for DNV GL’s international healthcare
services including the Accreditation Programs for Hospitals, Primary Care Providers and Specialist Outpatient Clinics, as well as the new and novel risk-based program aimed at supporting healthcare organizations improve management of infection risk (MIR).

Rajii Mehdwan_Administrerende direktør
Rajji Mehdwan
General Manager for Roche Pharmaceuticals in Norway.

Roche is a world leading company in Pharmaceuticals and Diagnostics and has focused on bringing innovative medicines & diagnostics to market via personalized healthcare strategies. Roche was named the most sustainable company of the year in healthcare in 2017. Roche was also named as the leading company in healthcare for investment in research and development with over 84 billion Nok invested in R&D in 2017. Rajji is passionate about the next era of personalized medicine and advances we can make to provide even better and targeted healthcare to Norwegian patients. She has taken concrete steps to invest in personalized approaches in Norway leveraging Roches investment in Genomics and Health Data. She is looking forward to meeting and learning from other colleagues at the conference to generate ideas on how we can ‘Co-Create’ to benefit our communities in Norway.

Marita Rodriguez
Ph.D. Biomedical Scientist and Engineer

Marita Rodriguez received her Ph.D. in Mechanical Engineering from the University of Washington in Seattle. Her dissertation work focused on the development of engineered microenvironments capable of assessing and enhancing the structural and functional maturation of human cells. After concluding her Ph.D., Marita conducted a postdoctoral research position in tissue engineering at the Hamburg-Eppendorf University Medical Center in Germany. Upon completing her postdoctoral position, Marita relocated to Stavanger and became involved in the 37 Degrees Conference as a means to get in touch with the local life science community. She is looking forward to hearing about the recent advancements in the field of digital healthcare, making connections with local and international members of this community, and participating in the conference as a panel moderator.

Ketil Widerberg
Chairman of the Board of Oslo Cancer Cluster Incubator

Ketil F. Widerberg, MBA, is General Manager of Oslo Cancer Cluster and Chairman of the Board of Oslo Cancer Cluster Incubator.
He builds on a long experience in realizing new projects within oncology in the biopharmaceutical company Photocure ASA in collaboration with academic institutions and international commercial partners.
Ketil has a broad operational experience ranging from explorative project management to being responsible for business development.
Widerberg’s educational background spans from preclinical medical school to management studies. He also holds a MBA from the University of Cambridge.

Marius Ødegaard
Marius Øgaard
Partner at ShareLab

Solid background from the ICT industry in R&D and product development. Experienced within sales, development of new markets, and business development. Significant international exposure (Western Europe, Asia/Pacific, Middle East, North-, and South America).
Has been working with innovation, entrepreneurship and industry cluster development since 2009. Initiator and founder of The Life Science Cluster, the Cutting Edge Festival, the Build2Grow entrepreneurship programme, and the Science for Society entrepreneurship programme. Initiator and editor of BioVerdi, a report on the future of the Norwegian bioeconomy.
Specialties: Industry clusters and networks, wireless and satellite communications, science & technology, business development and international sales. Certified Ideastronaut (!)


Roar Feedt
Chief Officer Business Development, Felleskjøpet Rogaland Agder SA (FKRA) CEO, AM Nutrition AS

Responsible for business development in Felleskjøpet Rogaland Agder (FKRA) SA. He is heading the development of FKRA subsidiaries within the fields of raw materials, ingredients and petfood.
Has since 2012 been the CEO of AM Nutrition AS, leader supplier of pea-based products for the global market of ingredients.


Richard F. Cowburn
PhD, Responsible Corporate Affairs

Richard F. Cowburn is responsible for facilitating and establishing academic and industry partnerships at Karolinska Institutet.
Dr Cowburn has been involved in research and development activities since 1980 and has 25 years of experience in the area of neuroscience.
He obtained his PhD at the Imperial College, London and did his postdoctoral education at Karolinska Institutet. In 2006 he was recruited as senior scientist to AstraZeneca where he was responsible for the strategic direction to the neurology project pipeline and the delivery of novel targets for Alzheimer’s and Parkinson’s disease drug discovery programmes.
At AstraZeneca Dr. Cowburn was also responsible for academic collaborations and strategic assessment of in-licensing opportunities. He became Adjunct Professor at Karolinska Institutet in 2007.
He has developed externalization skills, including scientific evaluations and deep fact finding, as well as scouting for new opportunities. Strong experience of team leadership and man management, with a record of driving performance and developing and coaching people.

Jens Nordahl

Jens Nordahl
Vice President Sales & Marketing for Smartfish AS

Jens started as a Board Member but took over as CEO for 8 years and led the development of the company from a small consumer product company with a handful of private investors to a science driven development company with focus on medical nutrition for patients with cancer and COPD, and with large institutional VC owners.
Before his career with Smartfish Jens had international product, marketing and general management positions driving product and concept innovation and business development with leading lifestyle brands such as Rollerblade, Benetton, Nike, and Guess by Marciano.
Jens has an MBA from SDA Bocconi in Milano.


Arild Kristensen
Manager Health & Care Technology Incubator

Arild holds a degree in economics and business administration from Heriot-Watt University, Edinburgh. He has extensive sales experience as a manager, entrepreneur, and consultant in companies such as IBM, Datus (iSolutions), Metier, and Eskaler. Arild holds several board positions and is project manager for the Norwegian Smart Care Cluster program.


Anders Haugland
Board Member, Norsk Innovasjonskapital II

Mr. Anders Haugland serves as a Managing Director at Bergen Teknologioverføring AS. Mr. Haugland serves as Board Member at Norsk Innovasjonskapital II.


Enrico Baraldi
Professor of Industrial Engineering & Management

Enrico Baraldi is Professor of Industrial Engineering & Management at the Department of Engineering Sciences, Uppsala University, and was core member of the IMI-financed DRIVE-AB project (Driving Reinvestment in R&D and Responsible Antibiotic Use), where he focused on the design and simulation of alternative economic models for stimulating antibiotics R&D. He currently leads PLATINEA, a Swedish multi-sectoral collaboration platform to support innovation, improved use and availability of existing antibiotics.
Enrico Baraldi has 20 years of experience as researcher and consultant in the area of business and product development in complex inter-organizational networks from several industries (ICT, biotech, medtech, furniture, automotive, etc.). Next to value and supply chain analysis he specializes also in the field of innovation management, strategy development and commercialization of science. His research is published in, among others, California Management Review, European Management Journal, Technovation, Industrial Marketing Management, Journal of Business Research, Science & Public Policy, the American journal of law & medicine, and The Lancet, Infectious Diseases. Enrico Baraldi is also engaged as ongoing evaluator of EU’s Regional Development Fund projects in the area of med-tech private-public partnerships and university commercialization strategies.


Nieves Cubo Mateo
Spanish National Research Council UCM/CSIC

Nieves Cubo Mateo is Graduated in Industrial Engineering & Automatic and has Master of Science and Materials Engineering by the University Carlos III de Madrid (UC3M). She remained in that institution for two years more as assistant researcher and teacher in the area of Tissue Engineering, at the Department of Bioengineering and Aerospace Engineering. There, she carried out his research on the printing of human tissues within the framework of Regenerative Medicine and 3D Printing. Now she continues researching in the field of human tissue regeneration through Bioprinting as a PhD student in the National Research Council of Spain (CSIC).


Sjur Svaboe
CEO Biolink Group

Sjur Svaboe is a serial entrepreneur having established more than 20 companies. In the late 60`ties he discontinued his studies in mathematics at the University of Bergen in Norway to become a software expert and later a large account representative in IBM.
Early in the 70`ties he formed his first own, successful software company. This company grew to NOK 2 billion in turnover and 2000 employees during 13 years, providing Svaboe with a small fortune when realizing his values. Multiple new successful software companies were established adding to his economic success.
In the early 80`ties he built an industrial greenhouse concentrating on biotechnology.
Mr. Svaboe founded the company holding the patented SPDA technology later being the fundament of Axis Shield for 20 years. The technology is installed in more than 30.000 medical doctor offices worldwide.
Svaboe also in the early eighties founded a world leading company within fish farming R&D, later ending up in the fish-farming food company Ewos. This Swedish company was in 2017 sold to the American company Cargil at an amount of NOK 12 billion. Other biotech companies were added in the 80-ties.
At the end of the 90`ties, Mr. Svaboe and associates founded Biolink Group AS, based on 20 years of research in flavonoids, and anthocyanins at the University of Bergen. Biolink Group soon had three wholly owned subsidiaries, Polypohenols AS, Medpalett AS and Biosynth AS.
In Q1 2016 Mr Svaboes Biolink Group realized its daughter company Medpalett at a very sizable amount of money.
Biosynth is in 2017 building a hightech processing plant, being the only one in the world able processing synthetic anthocyanin molecules in volume. Such molecules have already been shown possessing remarkable preventive- and disease-treatment qualities.
New exciting biotech developments are being planned.


Thorleif Jansen
Medical Director KRY

Thorleif Jansen, M.D. is the Medical Director of KRY in Norway. He is a specialist in Family Medicine and worked in General Practice in Norway for more than 12 years, including many years in rural parts of the country. He has also worked as a University Lecturer for NTNU (The Norwegian University for Science and Technology), tutoring medical students.
KRY offer video consultations with Norwegian doctors and psychologists.


Frode Forland
Norwegian Institute of Public Health

Frode Forland (MD, DPH) is Director of Infectious Disease Prevention and Control at the Norwegian Institute of Public Health. He is responsible for Surveillance, Antimicrobial Resistance and Advice and is the Chair of the Norwegian Antibiotic Committee. He initiated and led the ‘Global Health Preparedness Program’ under the ‘Global Health Security Agenda’, supporting Malawi, Palestine, Moldova and Ghana in building capacity for health security and implementing the International Health Regulations. Before returning to Norway, three years ago, he worked at the Royal Tropical Institute in Amsterdam to establish the ‘Collaboration for Evidence Based Healthcare in Africa’ and at the European Center for Disease Prevention and Control in Stockholm with the Development of methods for Evidence Based Public Health in Europe. Previously he was the Director of the Division for Primary Health Care at the Norwegian Directorate of Health and the Department for Guidelines, Prioritization and Quality improvement. He has worked several years in Africa and was a Board Member of Guidelines International Network for four years. He is the Vice Chair of the Norwegian Forum for Global Health Research. Frode has a keen interest in Global Health, Public Health, Antimicrobial Resistance and Evidence Based Healthcare.

Erling Nordbø
Managing Partner, Aleap

Erling has been a leader in the global life science industry for more than 18 years, with experience spanning from large pharmaceutical companies to small biotech startups. Before starting up Aleap, Erling was General Manager in Shire Human Genetic Therapies, a company developing, manufacturing and marketing orphan drugs for rare diseases. Erling has also worked with a large range of Norwegian life science startups. Erling holds a Master’s in Business Administration, from the ESCP Europe in Paris, and Master in Exercise Physiology from the Norwegian School of Sport Science Oslo, Norway.
Aleap, facilitate innovation and value creation by developing an ecosystem for health startups that allow ambitious entrepreneurs and companies to create new products better and faster.


Kirsten Haugland
Head of department

Kirsten Haugland is Head of the Research and Prevention Department at the Norwegian Cancer Society. She is also a board member of Oslo Cancer Cluster since May 2015.
Ms. Haugland has been working in Norwegian Cancer Society since 2010. She has 25 years’ experience from hospitals and more than 15 in leadership positions. During many years in cancer care for children and their families, Haugland focused on organizational development and patient involvement. Ms. Haugland is also responsible for and engaged in different leadership development programs. Ms. Haugland holds a Master of Health Economics and Health Management from the University of Oslo and a Bachelor in Nursing with specialization in cancer care.
Ms. Haugland has participated to several leadership programs, among others an executive management program in strategy and innovation at INSEAD in 2014.
In the Norwegian Cancer Society she is responsible for the department that includes prevention, research, legal section, strategy and analysis and for the association’s cancer care. She has led and participated in the Norwegian Cancer Society’s activities and political involvement in the importance of effective antibiotics for cancer patients in the last year.


Michael Gelinsky
Prof. Dr., Professor and Head of Center for Translational Bone, Joint and Soft Tissue Research

Michael Gelinsky has studied chemistry and made his PhD in this discipline at Freiburg University (Germany). In 1999 he moved to TU Dresden and worked for about 10 years in the department of Materials Science, heading his own group at the newly founded Max Bergmann Center of Biomaterials since 2002.
In 2010 he was appointed as professor at the Medical Faculty and is leading since this time the Center for Translational Bone, Joint and Soft Tissue Research ( His work is focused on biomaterials and scaffold development, tissue engineering and regenerative therapies, mostly for musculoskeletal tissues. His group is also very active in the field of additive manufacturing of implants and tissue engineering constructs as well as biofabrication technologies.

Arne Blix
CEO, Friend Software Corporation

Arne is a proven tech-entrepreneur with several successful exits to his name. Naval Academy, Arne served most of his seagoing service on Norwegian attack submarines. In 1995, Arne was hired by Det Norske Veritas (Classification Society – today DNV GL) and worked as Project Manager and Lead Auditor and headed prestigious projects in the Philippines, Panama and New York. In August 1998, Arne was headhunted by the Norwegian Shipowner’s Association as Head of Sections for Safety and Environmental issues and led their international lobbying efforts until he was requited by one of the member companies as chief commercial broker for a petrochemical ship transportation company, based in Houston, Texas. In 2002, Arne co-founded Accurate Equity, a FinTech SaaS and professional services company within equity based incentives design, accounting, valuation and disclosure, and bootstrapped it as CEO from scratch until 2013 where he took a board position and focused on the sale of the company. In 2015, the company was sold to Montagu Private Equity and merged with the share-plan and wealth management service of UBS, together with a portfolio of their 100 largest customers which combined today is the company Equatex. As investor and Chairman of MeaWallet, a FinTech SaaS infrastructure company enabling open loop mobile payment as a service (cloud based secure element, host card emulation and tokenization, adaptable front-end), Arne led the re-structuring of the business and in July 2016, he successfully sold the company to Seamless Distribution AB (Nasdaq; SEAM). Arne has an MBA from the Norwegian School of Economics (NHH) and the Norwegian University of Technology and Science as well as a degree in maritime law.


Anne Lise Waal

Anne Lise Waal is the CEO/CTO of technology startup Attensi – a leading developer of simulation based training in 2D, 3D, AR and VR. In the health care sector, Attensi is known for projects delivered to Sykehuset i Østfold, Sykehuset I Vestfold Aleris, RVTS as well as several large RnD projects, including INTROMAT.
Anne Lise has worked in the gaming industry for more than a decade and is passionate on how technology and principles from game development can be used in the health care sector to create measurable real world impact.


Saara Malkamäki

Saara Malkamäki works as a Specialist in Sitra, the Finnish Innovation Fund. Sitra is a future-oriented public think-and-do tank that promotes sustainable well-being and Finland’s competitiveness.
Saara builds fair data economy and engages people across Europe to create an international protocol for human-driven data exchange. In parallel, and over the past few years Saara has been boosting health and social care innovations and setting up a one-stop shop for Finnish well-being data.

Dan Shwarzman
CEO, MindUP – the Digital Health Incubator

Dan has been a leader in the global healthcare technology industry for over 15 years, with experience spanning Fortune 500 companies in the U.S. to Israeli startups. Prior to joining MindUP, Dan was CEO and President of Virtual Ports Inc., a company developing, manufacturing and marketing innovative products to improve laparoscopic surgery. Prior positions include General Manager (EndoTool Business Unit) and Director of Strategic Marketing for Hospira Worldwide, Inc., a global specialty pharmaceutical and medication delivery company, and senior positions at Johnson & Johnson (Ethicon and Ethicon EndoSurgery) and LifeWatch, Inc. Dan holds a Master’s in Business Administration, with Honors, from the University of Chicago Booth School of Business, and a Bachelor of the Arts, Cum Laude, in Economics and Business Administration from the University of Haifa, Israel.
MindUP, Haifa’s Digital Health Incubator is a joint venture of Medtronic, IBM, Pitango Venture Capital, Impact 1st Investments and Rambam Medical Center in collaboration with Israel Innovation Authority.

Thor Ole Gulsrud portrett 2

Thor Ole Gulsrud
Research Director

Thor Ole Gulsrud holds an MSc degree in Signal Processing from the University of Strathclyde in Glasgow, UK, and a PhD degree in Medical Signal and Image Processing from Aalborg University in Denmark. He has extensive and broad experience with medical and health technology and has also worked within the oil & gas sector. Currently he holds the positions as Research Director for MedTech at International Research Institute of Stavanger (IRIS) and Associate Professor in Health Technology at the University of Stavanger. He is also the project manager for Norway Pumps & Pipes and HelseCampus Stavanger.
IP Pragmatics
IP Pragmatics

Rupert Osborn
CEO IP Pragmatics Limited

Dr Rupert Osborn has worked in the field of technology commercialisation since 1996. His specific areas of expertise are transaction support (particularly licensing strategy and negotiation) and innovation management and strategy. He helps organisations embrace open innovation through strategic intellectual property advice, training and hands-on deal making support. His experience covers the commercialisation of different forms of intellectual property including trademark, copyright and patent licensing. He has particular expertise in the food and agriculture sectors. Rupert has an MA from Cambridge University and a PhD from Warwick University. In 2004 he co-founded IP Pragmatics, a management consultancy specialising in scientific technologies and intellectual property. The company is headquartered in London with offices in Scotland and Australia. The company also has strategic partners in Japan and North America. The company’s clients include universities, research institutes, SMEs, large enterprise and public sector organisations in over 20 countries.


Alexander Wentzel
SINTEF Indutry, Dept. of Biotechnology and Nanomedicine

Dr. Wentzel works as a Senior Researcher at SINTEF Industry, Dept. of Biotechnology and Nanomedicine.
He studied Biology at the Georg-August-University in Göttingen, Germany, where he also finished his PhD in Molecular Biology in 2003.
During his post-doctoral period at NTNU and SINTEF in Trondheim from 2005-2010, he has been working on research projects within the fields of microbial upgrading of crude oil (financed by VISTA) and Systems Biology understanding of the metabolic switch to antibiotics production by the model Actinobacterium Streptomyces coelicolor.
Dr. Wentzel’s current main research focus and interest is on developing efficient tools for accessing the vast biodiversity of microorganisms in nature for the discovery and development of new products for the enzyme and biopharmaceuticals market, as well as the biooeconomy.
Within this field, he currently coordinates the ERA-IB project OXYPOL, the ERA-CoBioTech project BESTER, the ERASysAPP project SYSTERACT, the Centre for Digital Life Norway project INBioPharm. In addition, he is SINTEF PI in several national and European projects, including the Horizon 2020 project MetaFluidics.


Ingrid Teigland

Ingrid Teigland Akay is a Managing Partner at Hadean Ventures. She has been a life science investor for the last 10 years, investing in European and US start-ups. Ingrid previously practiced as a medical doctor within internal medicine and surgery at hospitals in the UK and Norway. She holds a medical degree from Hanover Medical School, Germany, and an MBA in Finance from the London Business School.
Hadean Ventures is a European life science investment firm with offices in Oslo, Norway, and Stockholm, Sweden. Hadean Ventures invests into private life science companies within biotech, medtech and digital health across Europe with a particular focus on the Nordic region.

Jan Nygård, Kreftregisteret, foto Ann-Elin Wang stort

Jan F. Nygård
CIO The Cancer Registry of Norway

Dr. Jan F. Nygård is the head of the department of Registry Informatics at the Cancer Registry of Norway. He received his engineering degree in Cybernetics from Oslo College of Engineering in 1991, a Bachelor in Political Science in 1998 and a PhD in Epidemiology in 2005 from the University of Oslo.
His research interest lies in the cross-section between big data analytics, epidemiology and registry informatics. He has published more than 40 original research papers in peer-reviewed journals. He has supervised MSc and PhD students from both informatics and medical faculties.
He worked at the Institute of Community medicine at the University of Oslo from 1992 to 1998. In 1999 he came to the Cancer Registry to work in the Screening Department where he did his PhD on the effectiveness of cervical cancer screening. From 2005, he headed the section of medical coding and registration, and had the responsibilities of extending the traditional cancer registration with clinical cancer registries. From 2007, he was the first head of the newly formed IT-department, which in 2012 changed into the Registry Informatics department. As Head of the Registry Informatics he is responsible for digitalisation of the Cancer Registry, including the development and deployment of an automated ICT-platform for cancer registration, as well as the development and deployment of an ICT-system for the three national cancer screening programmes in Norway.
He is a board member of the CERTUS SFI, as well as serving on several reference and steering committees. From July 2017 to December 2017, he was a visiting scientist at the Institute for applied Scientific Computing at the Lawrence Livermore National Laboratory in California, USA.
Specialties: Epidemiology, Cancer coding and registration, Big data analytics, IT-governance, Data privacy and secure computing.


Norbert Windhab
Vice President Strategic Projects in Health Care

Dr. Norbert Windhab is heading the function Strategic Projects at Evonik Business Line Health Care since 2009. He entered Degussa AG, now Evonik Industries in 2005 to initiate preclinical and clinical programs in nutraceutical product innovation and novel functional drug delivery excipients. Before, he was R&D head “Bioorganic Systems” at Aventis R&T from 1998 until 2001 and spun out the JV from Aventis SA with Nanogen Inc., CA, in the field of DNA-based diagnostics and drug-research as its founder and Managing Director. In 1996 he was R&D manager chip-diagnostics at Hoechst AG’s R&T.
In 1994 he joined Albert Eschenmoser’s laboratories (ETH-Zürich/ Scripps Institute, La Jolla CA) for post-doctoral research. He obtained his PhD in Biophysical Chemistry at Freiburg University in 1993 in the synthesis and bio-physical properties of bio-polymers and RNA model compounds. He holds board-memberships in the BIOSS excellence centre of the German Government and the Max Planck Institute of Plant Breeding (Genetics) in Cologne and CAESAR in Bonn and was member of the biotech venture fund Polytechnos II until 2005.
His work focusses in the fields of life-science growth options and supra-molecular chemistry, he holds numerous patents in peptide and nucleic acid actives chemistry, drug R&D and drug-delivery.

Einar Leirvik (1)

Einar Leirvik
DNV GL, Marine Cybernetics Advisory

Einar graduated with a MSc degree in Cybernetics from Norwegian University of Science and Technology in 2004.
From 2004 he served as a Project Manager and responsible for automation, robotization, efficiency improvement and new production plants for a large Norwegian chocolate manufacturer.
He joined Marine Cybernetics in 2010 – which is now part of DNV GL – to develop simulators and test regimes – and to test various drilling and well control systems.
In 2011 he was promoted as a Project Manager in Marine Cybernetics, and has since been responsible for testing of many different control systems and integrated solutions – from complete maritime and drilling packages for semi-submersibles, drillships and jack-ups to more stand-alone solutions as Cranes, Scrubber-systems and MPDs – to mention a few.

Bjarte Bøe

Bjarte Bøe
Head of welfare technology

Bjarte Bøe is head of department for telehealth, home care technology and assisted living in the city of Stavanger. He is a social anthropologist with long experience as a consultant within risk management and organisational change processes mainly in the oil and gas sector before starting in his current position. As head of department he is responsible implementing technological solution in the home care services provided by the city.

Josep Carbó Foto 2017 WEB

Josep Carbó
Director Global Business Development & Partner, Mediktor

Josep Carbó is an Industrial Engineer based in Barcelona and with more than 18 year of international experience in Management Consulting and more than 12 years of experience in the Health & Life Science Industries.
From 2010 to 2015 Josep led Accenture’s Health Management Business Service in Europe, Africa and Latin America. In that role Josep led projects and initiatives which aim was improving health services delivery particularly for chronic patients to raise their quality of life standard and improve health services efficiencies. In particular, Josep contributed in projects like the Multichannel Health Service Center in the Basque Country, the Case Management project based in predictive analytics in La Fé (Valencia) or TEKI, the Telemedicine Solution based on Kinect Technology for elder population in the Basque Country.
In October 2015, Josep joined MEDIKTOR as Global Business Development Lead and Partner.


Finn Holm
Partner EY

Finn Holm is a part of the EY’s industry group for the healthcare sector in Norway and the Nordic region. Finn graduated with Continued education in coaching, BI Norwegian Business School and MSc in Strategy and knowledge management
Finn has been working in the sector for more than 15 years, and for several years he has been a specialist consultant and director of research and development at Ringerike Hospital. Finn has led a wide array of consulting projects for clients within the Norwegian health care system, pharma, life science and public health
Finn has led transformations, change management programs, leadership training, implementations in over 50 different projects in Norwegian hospitals, institutions and companies during these years. It also includes improvement and efficiency projects, change management, organizational changes and cost improvements.
Finn has his core competence in the health sector, especially related to Lean, patient flow and process management and implementation of changes.
Finn has through his long experience in the health sector, both as a consultant and employed in hospitals, worked for many years with investigation and analysis related to organizational conditions. For example, projects that deal with interactions between departments and levels in the health sector. Finn has been leading and working on several projects where change, culture and communication have been key issues.

Foto: Svein Lunde, Helse Stavanger

Emiel Janssen
PhD Stavanger University Hospital

Dr. Emiel Janssen studied medical biology at the University of Amsterdam. He started his career at the Academic Medical Center in Amsterdam working on neurogenetics. In 2001 he moved to the department of pathology at the Stavanger University Hospital. He received his PhD in 2007 at the University in Bergen and is currently the head of the unit for quantitative and molecular pathology, head of the laboratory for molecular biology and head of the research group from the department of pathology. Since 2015 he is professor in Biomedicine at the University of Stavanger.
The group’s research is devoted to diminishing patient suffering from over –and undertreatment by developing better diagnostics for treatment decision making. The development, validation and implementation of new biomarkers is the main focus of our research. Among the candidate biomarkers microRNA is one group that is currently under investigation; all biomarkers are analysed by using image analysis tools and digital pathology to improve current diagnostics in pathology. Breast cancer, melanomas, gynaecological pre –and cancer and urological cancer are the main diseases which we investigate.


Kathrine Myhre
CEO Norway Health Tech

Kathrine Myhre established the health cluster Norway Health Tech (previously named Oslo Medtech) in 2009 and has since then been the CEO of the organization. Norway Health Tech was awarded NCE (Norwegian Centre of Expertise) by Innovation Norway’s cluster program in 2015 and received Gold Label-status by the European cluster organization in 2016 and is a non-for-profit member organization focusing on innovation in the health space.
She has a bachelor’s degree from the University of Oslo in political science and built on this for her Master degree in Political Science from the University of Reading, UK in 2001. She then went on to working with innovation strategies and business creation based on novel research from the University of Oslo (UiO) until 2008 – from 2004 until 2008 as the Director of Innovation at Birkeland Innovation (now Inven2), the technology transfer office at University of Oslo.
From 2008 she held the position as Director of Innovation at the company IT Fornebu. It was from this position the concept of Norway Health Tech was formed and launched in 2009.
Kathrine Myhre has initiated and led numerous strategic and innovative processes and projects, within a broad spectrum: conduction of creative processes, market analysis, business creation, handling of IPR, marketing and sales and facilitating financing of key projects and businesses.
Kathrine Myhre has over the years built a solid network in the health sector, nationally and globally, and is a renowned speaker in the field of health innovation and technology.

Jacob Bergsland

Jacob Bergsland
MD, PhD Oslo University Hospital

Jacob Bergsland, MD, PhD
Medical Faculty, Oslo University 1973, MD degree
General Surgery Specialist, State University of New York, Buffalo, NY USA 1981
Cardiothoracic Surgery Specialist, State University of New York, Buffalo, NY USA 1983
Chief Centre for Minimally Invasive Cardiac Surgery, Kaleida Health, Buffalo NY , 1996
Chief Centre for Heart Transplantation, Kaleida Health, Buffalo, NY 1994
International Director, Cardiovascular Surgery, University Clinical Centre, Tuzla, Bosnia 1998
Medical Director, BH Heart Centre, Tuzla, Bosnia 2008
Cardiac Surgeon and Researcher, Intervention Centre, Rikshospitalet, Oslo University Hospital 2002

Walter Stockinger
Managing Partner, Hadean Ventures

Dr. Walter Stockinger is co-founder and Managing Partner at Hadean Ventures, a pan-European life-science venture fund based in Oslo. Hadean Ventures invests into start-up companies, which develop patient focused healthcare products across all relevant technologies including devices, drugs, diagnostics and e-health with a strong focus on clinical efficacy.
His previous experiences include almost a decade of venture capital investing with a global VC fund, healthcare consulting at the Boston Consulting Group and post-doctoral research at Harvard University. Walter has a Master’s degree in Biochemistry and a PhD in Molecular Biology from the University of Vienna.

Foto: Svein Lunde, Helse Stavanger

Thomas Lindner
MD, PhD, Director RAKOS

Thomas Lindner MD PhD is the Director at the Regional Competence Centre for Emergency Medicine (RAKOS) in the Western Norway Regional Health Authority. The RAKOS is responsible for research, development, education and implementation in the field of prehospital emergency medicine in this region. RAKOS is working by date with the implementation of prehospital diagnostic tools for presumed stroke patients and with advanced treatment options for patients with out of hospital cardiac arrest.
Further, RAKOS is a member in the regional advisory board for the planning and development for prehospital systems for patients with stroke symptoms.
Dr. Lindner has planned, developed and implemented the Norwegian mobile stroke unit (MSU) together with the hospital trust in south east Norway and the Norwegian air ambulance foundation. The MSU is an ambulance car equipped with a mobile cranial computertomograph and picture transfer possibilities to the hospital for diagnostic and treatment of patients with stroke symptoms. He is an international acknowledged speaker for the topic of prehospital systems for stroke patients.
Dr. Lindner is also the medical head of the Stavanger Acute Medicine Foundation for Education and Research (SAFER). The SAFER foundation is a simulation centre where health care professionals enhance their abilities in the treatment of acute injured or ill patinets. The SAFER centre is the major developer of course concepts for offshore nurses and contributes in the research of simulation pedagogics.
Dr. Lindner has been a physician since 1995 and started his career as an anaesthesiologist at Stavanger University Hospital in 2001. He has been a consultant in anaesthesia since 2006 and is working as a physician in the helicopter emergency medical service at the Stavanger University Hospital. The topic of his PhD was out of hospital cardiac arrest, and his current research is in the field of prehospital diagnostic and treatment systems.


Steinar Thoresen
Medical Director Abbvie

Steinar Thoresen
2013- Medical Director AbbVie Norway
2013-2017 Head R&D Group The Pharma Trade Org Norway
2006-2013 Head of Clinical Research, Medical Director Norway Denmark and Iceland GlaxoSmithKline
1999-2013 Professor ll University of Bergen
1992-2006 Head National Cervical- and Breast-Cancer Screening, The Cancer Registry of Norway
1990-1991 Visiting scientist Harvard Medical School, Boston
1985-1990 Head of Registration, The Cancer Registry of Norway
1979-1984 Pathologist PhD Haukeland University Hospital
2016- Board member Bergen Biomedical
2017- Head OCC Election Committee


Egil Greve
CEO Kappa bioscience, Vitamin K-2

Egil Greve is an entrepreneur with broad executive experience from building up companies and business units within the multi-national companies Norsk Hydro ASA, Yara International ASA and Akzo Nobel. He also headed several SMBs before he was asked to build up Kappa Bioscience in 2009.


Tamara Mansfeld
Global Innovation Lead, Pfizer Corporate Strategy

Tamara and her team are responsible for monitoring the external environment, identifying and sourcing digital innovation into Pfizer and accelerating new digital health capabilities to create long-term impactful disruptions across Pfizer.
Prior to her current role, Tamara served as the External R&D and Worldwide Innovation Liaison for Pfizer in Israel identifying potential partners in digital health and R&D.
Between 2004 and 2015, Tamara served as Senior Advisor in R&D Finance, and worked in the Portfolio & Decision Analysis (PDA) Team, helping Pfizer maximize the value of its R&D portfolio. During her tenure in PDA, Tamara has led a variety of asset teams and projects across the company, including: Biosimilars Portfolio Lead, Japan Liaison, Lifecycle Planning, asset co-developments with other companies, and a number of licensing and M&A projects.
Before joining Pfizer Tamara worked in management consulting and graduated from the Johnson Business School at Cornell University in 2004.
In her spare time, Tamara enjoys working out, volunteering in her community and spending time with her husband and three kids.


Laurent M. Saunier
Head of department at VINNOVA

Laurent Saunier heads the life science department at VINNOVA. The innovation agency invests $450m in health related projects every year. 700 projects are currently running with a particular focus on digital health, biologics and system innovation. Prior to joining VINNOVA, Laurent worked most of his career in the healthcare industry, leading organizations across the Northern Europe market within the area of medical imaging, medical devices and radiopharmaceuticals. Laurent holds MSc’s in both computer science and medical engineering.


Suzy Scholl
Coordinator of Translational Program in Gynecological Cancer

Suzy Scholl is the coordinator of the RAIDs consortium (Rational Molecular Assessment Innovative Drug selection) and senior consultant in translational research for gynaecological cancers.
Following her medical graduation from (CHU Pitié-Salpétrière, Université de Paris VI), Dr Scholl was awarded a Fogarty fellowship in the Breast Cancer Section – Medicine Branch NCI – NIH, Bethesda, USA. At the end of her post graduate training in Cambridge and London UK, she obtained the MRCOG qualification in the UK for which she received an EU validation in the form of the Certificate of Specialist Training in Obstetrics and Gynaecology. She was awarded a Habilitation to direct research (HDR) from the Medical faculty of Cochin Port Royal Paris, France). Dr Scholl has a management degree in hospital management (IAE Université Paris 1 – Panthéon Sorbonne) in 1998 and is member of ESMO, ESGO, IGCS and AACR. As a senior medical oncologist at Institut Curie from 1987 till 2017, she initiated several early phase clinical trials in cervical and breast cancer. She was the translational research coordinator of the EORTC gynae group and actively participated in IGCS cervical cancer brainstorming.
Her main interests are precision medicine and new designs in patients’ stratification for optimal therapeutic strategies as a senior consult within the department of drug development and innovation, Institut Curie.

Sebastian Eckl

Sebastian Eckl
Dr. Med

Sebastian Eckl joined Siemens Healthineers after absolving a Residency in Radiology and Neuroradiology in Germany. He is working for Enterprise Services helping providers to optimize clinical pathways and challeng

Eulalie Landèche
R&D Scientist

After a five-year formation in bioinformatics and modelling at the engineering school INSA de Lyon (France), I joined Novadiscovery, pionner in in silico medecin (Lyon, France). Now biomodeler, I participate within different modelling projects in order to answers drug’s specific clinical questions.

Gard Thomassen

Gard Thomassen has an IT background and a PhD in Bioinformatics. Thomassen worked at the Oslo University Hospital as a PostDoc and was part of the team doing the first DNA exome and RNA transcriptome sequencing of tumor and normal samples in Norway om 2010. In 2012 Thomassen started at the University IT Centre (USIT) University of Oslo as project leader for building a system for storage, analysis and collection of personal sensitive data (TSD). These services now represent the national solution for large scale research on sensitive data and hosts more than 2 PiB of data, 170 users in more than 420 research projects, more than 550VMs and a 1500 CPU High Performance Computing cluster. TSD has also delivered the IT infrastructure for clinical deep sequencing at the Oslo University Hospital since 2015. Today, Thomassen is Division Head for Research Computing Services, and Assistant Director at USIT, and is responsible for supporting a range of subjects including Sensitive Data, Digital Humaniora, Statistics, Digital Collections, Mass Storage, AI and High Performance Computing.

Joakim Sundnes
Associate Professor and Chief Research Scientist

Joakim Sundnes works as Chief Research Scientist at Simula Research Laboratory in Oslo, Norway. His main research interests are in computational modelling of cardiac electrophysiology and mechanics, with a particular focus on multiscale models and the coupling of cell and tissue. His research activities range from developing numerical methods and computational software tools for solving the involved equations, to applying the models for investigations of fundamental cardiac physiology. Sundnes has worked with in silico cardiac research for nearly two decades and has a strong interest in understanding the challenges and potential benefits of moving computational models from the research lab into the clinic.

Oliver Heinze
Acting director of the Department of Medical Information Systems of the University Hospital Heidelberg

Dr. Oliver Heinze is a medical computer scientist by training, graduated from the University of Heidelberg. He holds the position of the acting director of the Department of Medical Information Systems of the University Hospital Heidelberg. His research topics include standardized, patient centric ehealth infrastructures for treatment and research. Oliver is author of numerous publications and speaker on national and international conferences. His work was distinguished by several awards. He is founder of phellow seven, a startup developing a mobile patient engagement platform.

Umair Aslam
eHealth Lead | MSD Norway

Umair Aslam has an academic background in Business, Entrepreneurship, and Economics from leading universities in the US and Europe. His professional working background range from the public health care sector, the startup scene and the consultancy world. Currently he is in pharmaceutical industry with MSD Norway. There he is leading the work to bring forward innovative digital solutions that supports better patient outcomes, address system inefficiencies and drive business value.
He is a technology strategist with deep insights about how new technology is bringing forward solutions, tools and frameworks that are transforming industries and the current way of operating and creating value.

Morten Isaksen
Morten L. Isaksen
CEO of Bio-Me

Dr. Isaksen earned his doctorate in Biotechnology from the University of Oslo in 1993. As part of his doctorate, he was visiting scholar at UC Berkeley from 1990 – 1991, and at The European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany in the fall of 1991. He has since had extensive experience with commercial biotech; established and run several biotech companies in Norway and the UK, and has acted as consultant for many others. Most recently, he set up and was the CEO of the gut microbiome company Genetic Analysis from 2008 to 2013. He is the Founder and CEO of Bio-Me, which was established in 2016.

Trond Helgerud
Trond Helgerud
Alginate and Carrageenan R&D Manger, Managing Director FMC BioPolymer AS

Trond is Alginate and Carrageenan R&D Manager at DuPont Nutrition and Health, and Managing Director of FMC BioPolymer AS. He graduated as MSc in organic chemistry and petrochemistry from the University of Oslo in 1984. After some years in refinery catalyst contract research at SI in Oslo (now SINTEF) he joined Pronova Biopolymer in 1992 as laboratory manager and has since then been working with biopolymers and products derived from seaweeds in various positions. Current responsibilities include development of new product technology based on alginate, carrageenan and their brown and red seaweed sources. The alginate activities in Norway (FMC BioPolymer AS) have been part of FMC Corporation since 1999 and were acquired by DuPont in 2017. Trond holds board positions in FMC BioPolymer AS, DuPont Norge AS and AlgiPharma AS.</h5